Landmark Decision Unequivocally Places KÄÄPÄ Biotech as the Leading European Functional Mushroom Provider
KÄÄPÄ Biotech, a biotechnology company that researches, innovates and develops functional mushroom products, today announced that the European Food Safety Authority (EFSA) has evaluated and validated their NordRelease™ extraction process for mushroom extracts. This landmark decision justifies the years of research and development by the teams at KÄÄPÄ Biotech to set a new standard of excellence in the functional mushroom and nutraceutical space. It places KÄÄPÄ Biotech as a world leader for bioactive content and quality testing.
Alongside traditional water extraction, the NordRelease™ extraction process is now the only extraction process to have been approved by the EU for functional mushroom extracts. This official non-novel status for KÄÄPÄ Biotech’s NordRelease™ mushroom extract powders represents the largest innovation in this space in decades and firmly demonstrates that KÄÄPÄ Biotech is dedicated to leading the way in this industry.
This EFSA approval is another step by KÄÄPÄ Biotech towards bringing its customers the absolute best quality functional mushroom products, having achieved FSSC 22000 approval in early 2023. The FSSC 22000 scheme provides a certification model used in the food manufacturing industry and the related supply chain to ensure food safety standards and processes.
“We’re beyond thrilled that EFSA has verified what we knew all along. That our NordRelease™ extraction process provides the best quality to our customers. This extraction process is undeniably the best way to extract the bioactive compounds from mushrooms versus traditional water extraction”, said Eric Puro, CEO & Co-Founder of KÄÄPÄ Biotech. “We have an amazing team doing incredible work in this space. The functional mushroom market continues to grow at an incredible rate and we’re proud to not only be a part of it, but to be taking it in exciting new directions. Over 180 customers have put their trust in us to deliver on our promises of bringing them the best quality product, with today’s announcement signallying that we’re doing just that.”
NordRelease™, based upon Ultrasonic Assisted Extraction (UAE), was developed and created by the science team at KÄÄPÄ Biotech . After years of pioneering and evolving UAE, KÄÄPÄ Biotech took the initiative to trademark its proprietary extraction technology in an effort to highlight the gulf in quality often seen in the market.
As recently as 15.04.2025 KÄÄPÄ Biotech announced that it had closed a €900,000 strategic investment from PeakBridge, a pioneering global fund manager in agri-food and a member of the Edmond de Rothschild Private Equity partnership. This strategic investment will help drive a new phase of growth as KÄÄPÄ Biotech continues to scale its business to match the increase in customer demands.
In September 2024, KÄÄPÄ Biotech announced it had opened a new state-of-the-art growing facility in Paimio, Finland.